# Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)

> **NCT00073255** · PHASE1 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 12 (—)

## Conditions studied

- Diabetes Mellitus, Insulin-Dependent

## Interventions

- **DRUG:** hokt3g1 (ALA-ALA)

## Key facts

- **NCT ID:** NCT00073255
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 12 (—)
- **Last updated:** 2010-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073255, "Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00073255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*